PURE Bioscience Receives Favorable NASDAQ Listing Decision

PURE Bioscience Receives Favorable NASDAQ Listing Decision 
SAN DIEGO, CA -- (Marketwired) -- 04/25/13 --  PURE Bioscience
(NASDAQ: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, today announced that the NASDAQ Listing
Qualifications Panel (the "Panel") has granted the Company's request
for continued listing on The NASDAQ Capital Market pursuant to an
extension through June 18, 2013 to evidence compliance with the
minimum $2.5 million stockholders' equity requirement and its ability
to sustain compliance with the minimum threshold over the long term. 
The determination follows the Company's hearing before the Panel on
April 4, 2013, at which the Panel considered the Company's plan to
regain and sustain compliance with the minimum stockholders' equity
requirement. While the Company is working diligently to satisfy the
terms of the Panel's decision, there can be no assurance that the
Company will be able to timely do so or that the Panel will grant any
additional extensions. 
About PURE Bioscience, Inc.
 PURE Bioscience, Inc. develops and
markets technology-based bioscience products that provide solutions
to numerous global health challenges, including Staph (MRSA) and
Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's
proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials,
represent innovative advances in diverse markets and lead today's
global trend toward industry and consumer use of "green" products
while providing competitive advantages in efficacy and safety.
Patented SDC is an electrolytically generated source of stabilized
ionic silver, which formulates well with other compounds. As a
platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and
the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com. 
Forward-looking Statements
 This press release includes statements
that may constitute "forward-looking" statements, usually containing
the words "believe," "estimate," "expect," "intend," "project" or
similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed initiatives and business plans, acceptance of the Company's
current and future products and services in the marketplace, the
ability of the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release. 
Investor Relations Contact:
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
PURE@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.